After targeting struggling biotechs, Tang’s Concentra shifts gears with unsolicited bid for LianBio
Tang Capital Management has made its fifth unsolicited acquisition bid of the year, this time for US-Chinese company LianBio. The choice of target marks a notable change in strategy for the California investment group, which had opted to proposition struggling early-stage biotechs in 2023.
LianBio is in a relatively strong position compared with Tang’s previous targets, which include Atea Pharmaceuticals, Jounce Therapeutics, Rain Oncology and Theseus Pharmaceuticals. LianBio has several partnered products on the market and has benefited from a recent spate of clinical successes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.